Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Diabetes Care

• Publication date

  2005-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/DIACARE.28.5.1151PMID 15855581
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

  2007cited by this paper
• British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

  2004cited by this paper
• Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

  2004cited by this paper
• Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IV

  2004cited by this paper
• European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension

  2003cited by this paper
• 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.

  2003cited by this paper
• MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

  2003cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

  2002cited by this paper
• Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

  2002cited by this paper
• Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial

  2001influential reference
• PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA

  2000cited by this paper
• Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation

  1998cited by this paper
• Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation

  1998cited by this paper
• Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

  1998cited by this paper
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38

  1998cited by this paper
• Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

  1998cited by this paper
• So What's the Difference Between Teenage Beys and Girls, Anyway?

  1997cited by this paper
• U.K. Prospective Diabetes Study 27: Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex

  1997cited by this paper
• Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

  1997cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

  1995cited by this paper
• Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications.

  1993cited by this paper
• Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial

  1993cited by this paper
• Diabetes and cardiovascular disease. The Framingham study.

  1979cited by this paper

• Management of dyslipidaemia in patients with comorbidities: facing the challenge: type 2 diabetes mellitus

  2025cites this paper
• Антизапальний ефект аторвастатину в пацієнтів зі стабільною ішемічною хворобою серця

  2025cites this paper
• Statin use and low-density lipoprotein cholesterol target achievement for primary prevention of atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus: a multicenter cross-sectional study in Sri Lanka

  2025cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026.

  2025cites this paper
• Investigating the role of genetic variations of ABCB1 (rs1045642) and CYP7A1 (rs3808607) genes on serum lipid level among Malaysian male patients treated with atorvastatin

  2025cites this paper
• Atherosclerotic Cardiovascular Disease in Cardiovascular-Kidney-Metabolic Syndrome.

  2025cites this paper
• First Iranian guidelines for the diagnosis, management, and treatment of hyperlipidemia in adults

  2024cites this paper
• SREBP1 induction mediates long-term statins therapy related myocardial lipid peroxidation and lipid deposition in TIIDM mice

  2024cites this paper
• Assessing real-world effectiveness of atorvastatin in patients with type 2 diabetes mellitus for the primary prevention of cardiovascular events.

  2024cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025.

  2024cites this paper
• Implications and hidden toxicity of cardiometabolic syndrome and early‐stage heart failure in carfilzomib‐induced cardiotoxicity

  2024cites this paper
• Dyslipidemia: A Narrative Review on Pharmacotherapy

  2024cites this paper
• Section 9: Pharmacologic Approaches to Glycemic Treatment

  2024cites this paper
• Optimizing lipid control in Taiwanese diabetic patients: A collaborative consensus by the Diabetes Association of the Republic of China (Taiwan) and the Taiwanese Association of Diabetes Educators

  2024cites this paper
• Inter‐relationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and management

  2024cites this paper
• Prescribing patterns of statins and associated factors among type 2 diabetes mellitus patients in Africa: A systematic review and meta-analysis

  2024cites this paper
• Trends and gaps in statin use for cardiovascular disease prevention in type 2 diabetes: a real-world study in Shanghai, China.

  2023cites this paper
• HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.

  2023cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024.

  2023cites this paper
• 10-Year Cardiovascular Risk in Patients With Newly Diagnosed Type 2 Diabetes Mellitus.

  2023cites this paper
• A review of the research on the cardiovascular risk factors and treatment options for Type II diabetic patients

  2023cites this paper
• Atorvastatin

  2023cites this paper
• Identifying Reasons for Statin Nonuse in Patients With Diabetes Using Deep Learning of Electronic Health Records

  2023cites this paper
• Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis

  2022cites this paper
• Blood Pressure and Blood Glucose Control and Associated Factors Among Adults with Hypertension at Three Public Hospitals in Southern Ethiopia

  2022cites this paper
• Statin use and the risk of CVD events, stroke, and all-cause mortality in patients with diabetes: A systematic review and meta-analysis.

  2022cites this paper
• Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials

  2022cites this paper
• Triglyceride-glucose index in the prediction of adverse cardiovascular events in patients with premature coronary artery disease: a retrospective cohort study

  2022cites this paper
• Assessment of Potentially Inappropriate Prescribing for People With Type 2 Diabetes Mellitus Using IMPACT2DM, a New Explicit Tool

  2022cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023.

  2022cites this paper
• Statins and renal disease progression, ophthalmic manifestations, and neurological manifestations in veterans with diabetes: A retrospective cohort study

  2022cites this paper
• Correlation Between Atherosclerotic Cardiovascular Disease Risk Factors and Statin Prescribing Patterns.

  2021cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022.

  2021cites this paper
• Predictive Value of the Triglyceride to High-Density Lipoprotein Cholesterol Ratio for All-Cause Mortality and Cardiovascular Death in Diabetic Patients With Coronary Artery Disease Treated With Statins

  2021cites this paper
• Principles of Diabetes Care and Lifestyle Modification

  2021cites this paper
• Are Statins the Optimal Therapy for Cardiovascular Risk in Patients with Diabetes? What Newer Agents Are There for the Treatment for Dyslipidemia in Diabetes? Are Triglycerides an Important Risk Factor for Diabetes?

  2021cites this paper
• Non-achievement of the Low-Density Lipoprotein Cholesterol Goal in Older Patients with Type 2 Diabetes Mellitus and a Very High Cardiovascular Disease Risk: A Multicenter Study in Vietnam

  2021cites this paper
• Current Practices and Gaps in Management of Dyslipidemia in Type 2 Diabetes Mellitus (T2DM) in Accordance with American Diabetes Association (ADA) Guidelines: A Subset Analysis from a Real-World, Cross-Sectional Observational Study (LEADD Study)

  2021cites this paper
• DMSO_A_294842 2693..2700

  2021cites this paper
• Dyslipidaemia in Type 1 Diabetes: Molecular Mechanisms and Therapeutic Opportunities

  2021cites this paper
• E cacy of Lipid-Lowering Therapy During Cardiac Rehabilitation in Patients With Diabetes Mellitus and Coronary Heart Disease

  2021cites this paper
• Triglyceride to high-density lipoprotein cholesterol ratio predicts all-cause and cardiovascular mortality in diabetic patients   with coronary artery disease on statin treatment

  2021cites this paper
• Efficacy of Lipid-Lowering Therapy during Cardiac Rehabilitation in Patients with Diabetes Mellitus and Coronary Heart Disease

  2021cites this paper
• Complex management in diabetic patients with cardiovascular disease

  2020cites this paper
• Features of postoperative therapy in patients with type ІІ diabetes

  2020cites this paper
• Contemporary lipid clinic and achievements in low-density lipoprotein-cholesterol reductions in very high-risk patients.

  2020cites this paper
• Hypertonie und Diabetes: Hochdruck bei Typ-2-Diabetikern-Eine besondere therapeutische Herausforderung

  2020influential citation
• Japanese Clinical Practice Guideline for Diabetes 2019

  2020cites this paper
• Japanese Clinical Practice Guideline for Diabetes 2019

  2020cites this paper
• Lipid Goals in Diabetic Patients. Clinical Implications after Application of a New Formula for LDL-cholesterol Calculation

  2020cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021.

  2020cites this paper
• Temporal decline in non-high-density lipoprotein cholesterol in subjects with diabetes mellitus without atherosclerotic cardiovascular disease.

  2020cites this paper
• The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA* Guidelines on the Management of Blood Cholesterol in Diabetes

  2020cites this paper
• Treating Dyslipidemias in the Primary Prevention of Atherosclerotic Cardiovascular Disease in Older Adults with Diabetes Mellitus.

  2020cites this paper
• Consumption and market share of cholesterol-lowering drugs in high-risk patients before and after the release of the 2013 ACC/AHA cholesterol guidelines: a retrospective observational study

  2020cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020

  2019cites this paper
• 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2019cites this paper
• Legacy Effect in the Treatment of Hypertension: Persistent Cardiovascular Protection after Conclusion of Randomized Clinical Trials in Hypertension

  2019cites this paper
• 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2019cites this paper
• Traitements complémentaires et parallèles du diabète Comité d’experts des Lignes directrices de pratique clinique de Diabète Canada

  2019cites this paper
• Statin prescription among patients with type 2 diabetes in Botswana: findings and implications

  2019cites this paper
• 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2019cites this paper
• Hypertonie und Diabetes: Hochdruck bei Typ-2-Diabetikern - Eine besondere therapeutische Herausforderung

  2019influential citation
• 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease.

  2019cites this paper
• 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary.

  2019cites this paper
• 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2019cites this paper
• 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2019cites this paper
• Le diabète chez les personnes âgées Comité d’experts des Lignes directrices de pratique clinique de Diabète Canada

  2019cites this paper
• Management of Low Density Lipoprotein Cholesterol at a primary care diabetes clinic in Kuwait.

  2019cites this paper
• Reduced expression of pyruvate kinase in kidney proximal tubule cells is a potential mechanism of pravastatin altered glucose metabolism

  2019cites this paper
• Lipid-Lowering Prescription Patterns in Patients With Diabetes Mellitus or Cardiovascular Disease.

  2019cites this paper
• Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!

  2019cites this paper
• 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2019cites this paper
• Investigator-initiated studies: Challenges and solutions

  2018cites this paper
• Dyslipidemia.

  2018cites this paper
• Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial

  2018cites this paper
• Cardiovascular Disease and Risk Management : Standards of Medical Care in Diabetes d 2019

  2018cites this paper
• Avant-propos Ars longa… iudicium difficile. L’exemple des recommandations dans les dyslipidémies du diabétique

  2018cites this paper
• Type 2 diabetes mellitus and dyslipidaemia: effects of genetic variation in African populations

  2018cites this paper
• Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin

  2018cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019

  2018cites this paper
• Diabetes in Older People.

  2018cites this paper
• Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study

  2018cites this paper
• 2 Ethnic Difference in Lipid Profiles

  2018cites this paper
• Cardiovascular outcomes trials with statins in diabetes

  2018cites this paper
• Postprandial hyperglycemia and postprandial hypertriglyceridemia in type 2 diabetes

  2017cites this paper
• Ethnic Difference in Lipid Profiles 17 Globalization of the western lifestyle contribute to worldwide increases of adiposity and type 2 diabetes

  2017cites this paper
• Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins

  2017cites this paper
• 9. Cardiovascular Disease and Risk Management.

  2017cites this paper
• A New HOPE? Lessons from Heart Outcomes Prevention Evaluation-3.

  2017cites this paper
• Implications of American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines on Statin Underutilization for Prevention of Cardiovascular Disease in Diabetes Mellitus Among Several US Networks of Community Health Centers

  2017cites this paper
• Trends in the management levels of metabolic risk factors in middle-aged and elderly patients with type 2 diabetes mellitus: The Korean National Health and Nutrition Examination Survey 1998–2014

  2017cites this paper
• Dyslipidaemia and its treatment in patients with type 2 diabetes: A joint analysis of the German DIVE and DPV registries

  2017cites this paper
• Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial

  2017cites this paper
• Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium–glucose co-transporter 2 inhibitors

  2017cites this paper
• 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018

  2017cites this paper
• Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.

  2017cites this paper
• Diabetes mellitus and stroke: A clinical update

  2017cites this paper
• Statins Use in Diabetes Patients as Primary Prevention and Low-Density Lipoprotein Cholesterol Levels

  2017cites this paper
• Percutaneous Coronary Intervention Rates and Associated Independent Predictors for Progression of Nontarget Lesions in Patients With Diabetes Mellitus After Drug-Eluting Stent Implantation

  2016cites this paper